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Abstract 11 
Eslicarbazepine acetate (ESL) is a dibenzazepine anticonvulsant approved as adjunctive treatment for 12 
partial-onset epileptic seizures. Following first pass hydrolysis of ESL, S-licarbazepine (S-Lic) 13 
represents around 95 % of circulating active metabolites. S-Lic is the main enantiomer responsible 14 
for anticonvulsant activity and this is proposed to be through the blockade of voltage-gated Na+ 15 
channels (VGSCs). ESL and S-Lic both have a voltage-dependent inhibitory effect on the Na+ current 16 
in N1E-115 neuroblastoma cells expressing neuronal VGSC subtypes including Nav1.1, Nav1.2, 17 
Nav1.3, Nav1.6 and Nav1.7. ESL has not been associated with cardiotoxicity in healthy volunteers, 18 
although a prolongation of the electrocardiographic PR interval has been observed, suggesting that 19 
ESL may also inhibit cardiac Nav1.5 isoform. However, this has not previously been studied. Here, 20 
we investigated the electrophysiological effects of ESL and S-Lic on Nav1.5 using whole-cell patch 21 
clamp recording. We interrogated two model systems: (1) MDA-MB-231 metastatic breast 22 
carcinoma cells, which endogenously express the ‘neonatal’ Nav1.5 splice variant, and (2) HEK-293 23 
cells stably over-expressing the ‘adult’ Nav1.5 splice variant. We show that both ESL and S-Lic 24 
inhibit transient and persistent Na+ current, hyperpolarise the voltage-dependence of fast inactivation, 25 
and slow the recovery from channel inactivation. These findings highlight, for the first time, the 26 
potent inhibitory effects of ESL and S-Lic on the Nav1.5 isoform, suggesting a possible explanation 27 
for the prolonged PR interval observed in patients on ESL treatment. Given that numerous cancer 28 
cells have also been shown to express Nav1.5, and that VGSCs potentiate invasion and metastasis, 29 
this study also paves the way for future investigations into ESL and S-Lic as potential invasion 30 
inhibitors. 31 
1! Introduction 32 
Eslicarbazepine acetate (ESL) is a member of the dibenzazepine anticonvulsant family of compounds 33 
which also includes oxcarbazepine and carbamazepine (1). ESL has been approved by the European 34 
Medicines Agency and the United States Federal Drug Administration as an adjunctive treatment for 35 
partial-onset epileptic seizures (2). ESL is administered orally and rapidly undergoes first pass 36 
hydrolysis to two stereoisomeric metabolites, R-licarbazepine and S-licarbazepine (S-Lic; also 37 
known as eslicarbazepine; Figure 1A, B) (3-5). S-Lic represents around 95 % of circulating active 38 
metabolites following first pass hydrolysis of ESL and is the enantiomer responsible for 39 
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anticonvulsant activity (6, 7). S-Lic also has improved blood brain barrier penetration compared to R-40 
licarbazepine (8). Although S-Lic has been shown to inhibit T type Ca2+ channels (9), its main 41 
activity is likely through blockade of voltage-gated Na+ channels (VGSCs) (10). ESL offers several 42 
clinical advantages over other older VGSC-inhibiting antiepileptic drugs, e.g. carbamazepine, 43 
phenytoin; it has a favourable safety profile (10, 11), reduced induction of hepatic cytochrome P450 44 
enzymes (12), low potential for drug-drug interactions (13, 14), and takes less time to reach a steady 45 
state plasma concentration (15). 46 
VGSCs are composed of a pore-forming a subunit in association with one or more auxiliary b 47 
subunits, the latter modulating channel gating and kinetics in addition to functioning as cell adhesion 48 
molecules (16). There are nine a subunits (Nav1.1-Nav1.9), and four b subunits (b1-4) (17, 18). In 49 
postnatal and adult CNS neurons, the predominant a subunits are the tetrodotoxin-sensitive Nav1.1, 50 
Nav1.2 and Nav1.6 isoforms (19) and it is therefore on these that the VGSC-inhibiting activity of ESL 51 
and S-Lic has been described. In the murine neuroblastoma N1E-115 cell line, which expresses 52 
Nav1.1, Nav1.2, Nav1.3, Nav1.6 and Nav1.7, ESL and S-Lic both have a voltage-dependent inhibitory 53 
effect on the Na+ current (10, 20). In this cell model, S-Lic has no effect on the voltage-dependence 54 
of fast inactivation, but significantly hyperpolarises the voltage-dependence of slow inactivation (10). 55 
S-Lic also has a lower affinity for VGSCs in the resting state than carbamazepine or oxcarbazepine, 56 
thus potentially improving its therapeutic window over first- and second-generation dibenzazepine 57 
compounds (10). In acutely isolated murine hippocampal CA1 neurons, which express Nav1.1, 58 
Nav1.2 and Nav1.6 (21-23), S-Lic significantly reduces the persistent Na+ current, a very slow-59 
inactivating component ~1 % the size of the peak transient Na+ current (24, 25). Moreover, in 60 
contrast to carbamazepine, this effect is maintained in the absence of b1 (24, 26). 61 
In healthy volunteers, ESL has not been associated with cardiotoxicity and the QT interval remains 62 
unchanged on treatment (27). However, a prolongation of the PR interval has been observed (27), 63 
suggesting that caution should be exercised in patients with cardiac conduction abnormalities (13). 64 
Prolongation of the PR interval suggests that ESL may also inhibit the cardiac Nav1.5 isoform, 65 
although this has not previously been studied. Nav1.5 is not only responsible for the initial 66 
depolarisation of the cardiac action potential (28), but is also expressed in breast and colon carcinoma 67 
cells, where the persistent Na+ current promotes invasion and metastasis (29-32). Inhibition of Nav1.5 68 
with phenytoin or ranolazine decreases tumour growth, invasion and metastasis (33-35). Thus, it is of 69 
interest to specifically understand the effect of ESL on the Nav1.5 isoform. 70 
In the present study we investigated the electrophysiological effects of ESL and S-Lic on Nav1.5 [1] 71 
endogenously expressed in the MDA-MB-231 metastatic breast carcinoma cell line, and [2] stably 72 
over-expressed in HEK-293 cells. We show that both ESL and S-Lic inhibit transient and persistent 73 
Na+ current, hyperpolarise the voltage-dependence of fast inactivation, and slow the recovery from 74 
channel inactivation. These findings highlight, for the first time, the potent inhibitory effects of ESL 75 
and S-Lic on the Nav1.5 isoform. 76 
2! Materials and methods 77 
2.1! Pharmacology 78 
ESL (Tokyo Chemical Industry UK Ltd) was dissolved in DMSO to make a stock concentration of 79 
67 mM. S-Lic (Tocris) was dissolved in DMSO to make a stock concentration of 300 mM. Both 80 
drugs were diluted to working concentrations of 100-300 µM in extracellular recording solution. The 81 
concentration of DMSO in the recording solution was 0.45 % for ESL and 0.1 % for S-Lic. Equal 82 
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concentrations of DMSO were used in the control solutions. DMSO (0.45 %) had no effect on the 83 
Na+ current (Supplementary Figure 1). 84 
2.2! Cell culture 85 
MDA-MB-231 cells and HEK-293 cells stably expressing Nav1.5 (a gift from L. Isom, University of 86 
Michigan) were grown in Dulbecco’s modified eagle medium supplemented with 5 % FBS and 4 87 
mM L-glutamine (36). Molecular identity of the MDA-MB-231 cells was confirmed by short tandem 88 
repeat analysis (37). Cells were confirmed as mycoplasma-free using the DAPI method (38). Cells 89 
were seeded onto glass coverslips 48 h before electrophysiological recording. 90 
2.3! Electrophysiology 91 
Plasma membrane Na+ currents were recorded using the whole-cell patch clamp technique, using 92 
methods described previously (32, 35). Patch pipettes made of borosilicate glass were pulled using a 93 
P-97 pipette puller (Sutter Instrument) and fire-polished to a resistance of 3-5 MΩ when filled with 94 
intracellular recording solution. The extracellular recording solution for MDA-MB-231 cells 95 
contained (in mM): 144 NaCl, 5.4 KCl, 1 MgCl2, 2.5 CaCl2, 5.6 D-glucose and 5 HEPES (adjusted to 96 
pH 7.2 with NaOH). For the extracellular recording solution for HEK-293 cells expressing Nav1.5, 97 
the extracellular [Na+] was reduced to account for the much larger Na+ currents and contained (in 98 
mM): 60 NaCl, 84 Choline Cl, 5.4 KCl, 1 MgCl2, 2.5 CaCl2, 5.6 D-glucose and 5 HEPES (adjusted 99 
to pH 7.2 with NaOH). The intracellular recording solution contained (in mM): 5 NaCl, 145 CsCl, 2 100 
MgCl2, 1 CaCl2, 10 HEPES, 11 EGTA, (adjusted to pH 7.4 with CsOH) (39). Voltage clamp 101 
recordings were made at room temperature using a Multiclamp 700B or Axopatch 200B amplifier 102 
(Molecular Devices) compensating for series resistance by 40–60%. Currents were digitized using a 103 
Digidata interface (Molecular Devices), low pass filtered at 10 kHz, sampled at 50 kHz and analysed 104 
using pCLAMP 10.7 software (Molecular Devices). Leak current was subtracted using a P/6 protocol 105 
(40). Extracellular recording solution ± drugs was applied to the recording bath at a rate of ~1.5 106 
ml/min using a ValveLink 4-channel gravity perfusion controller (AutoMate Scientific). Each new 107 
solution was allowed to equilibrate in the bath for ~4 min following switching prior to recording at 108 
steady state. 109 
2.4! Voltage clamp protocols 110 
Cells were clamped at a holding potential of -120 mV or -80 mV for ≥ 250 ms, dependent on 111 
experiment (detailed in the Figure legends). Five main voltage clamp protocols were used, as 112 
follows: 113 
1.! To assess the effect of drug perfusion and wash-out on peak current in real time, a simple one-114 
step protocol was used where cells were held at -120 mV or -80 mV for 250 ms and then 115 
depolarised to -10 mV for 50 ms.  116 
2.! To assess the voltage-dependence of activation, cells were held at -120 mV for 250 ms and then 117 
depolarised to test potentials in 10 mV steps between -120 mV and +30 mV for 50 ms. The 118 
voltage of activation was taken as the most negative voltage which induced a visible transient 119 
inward current. 120 
3.! To assess the voltage-dependence of steady-state inactivation, cells were held at -120 mV for 250 121 
ms followed by prepulses for 250 ms in 10 mV steps between -120 mV and +30 mV and a test 122 
pulse to -10 mV for 50 ms. 123 
  Eslicarbazepine effects on Nav1.5 
!
4 
4.! To assess recovery from fast inactivation, cells were held at -120 mV for 250 ms, and then 124 
depolarised twice to 0 mV for 25 ms, returning to -120 mV for the following intervals between 125 
depolarisations (in ms): 1, 2, 3, 5, 7, 10, 15, 20, 30, 40, 50, 70, 100, 150, 200, 250, 350, 500. In 126 
each case, the second current was normalised to the initial current and plotted against the interval 127 
time. 128 
2.5! Curve fitting and data analysis 129 
To study the voltage-dependence of activation, current-voltage (I-V) relationships were converted to 130 
conductance using the following equation: 131 
 G = I / (Vm – Vrev), where G is conductance, I is current, Vm is the membrane voltage and Vrev 132 
is the reversal potential for Na+ derived from the Nernst equation. Given the different recording 133 
solutions used, Vrev for Na+ was +85 mV for MDA-MB-231 cells and +63 mV for HEK-Nav1.5 cells. 134 
The voltage-dependence of conductance and availability were normalised and fitted to a Boltzmann 135 
equation: 136 
 G = Gmax / (1 + exp ((V1/2 – Vm) / k)), where Gmax is the maximum conductance, V1/2 is the 137 
voltage at which the channels are half activated/inactivated, Vm is the membrane voltage and k is the 138 
slope factor. 139 
Recovery from inactivation data (It / It=0) were normalised, plotted against recovery time (∆t) and 140 
fitted to a single exponential function: 141 
 t = A1 + A2 exp (-t / t0), where A1 and A2 are the coefficients of decay of the time constant 142 
(t), t is time and t0 is a time constant describing the time dependence of t. 143 
The time course of inactivation was fitted to a double exponential function: 144 
 I = Af exp (-t / tf) + As exp (-t / ts) + C, where Af and As are maximal amplitudes of the slow 145 
and fast components of the current, tf and ts are the fast and slow decay time constants and C is the 146 
asymptote. 147 
2.6! Statistical analysis 148 
Data are presented as mean and SEM unless stated otherwise. Statistical analysis was performed on 149 
the raw (non-normalised) data using GraphPad Prism 8.4.0. Pairwise statistical significance was 150 
determined with Student’s paired t-tests. Multiple comparisons were made using ANOVA and Tukey 151 
post-hoc tests, unless stated otherwise. Results were considered significant at P < 0.05. 152 
3! Results 153 
3.1! Effect of eslicarbazepine acetate and S-licarbazepine on transient and persistent Na+ 154 
current 155 
Several studies have clearly established the inhibition of neuronal VGSCs (Nav1.1, Nav1.2, Nav1.3, 156 
Nav1.6, Nav1.7 and Nav1.8) by ESL and its active metabolite S-Lic (10, 20, 24, 41). Given that ESL 157 
prolongs the PR interval (27), potentially via inhibiting the cardiac Nav1.5 isoform, together with the 158 
interest in inhibiting Nav1.5 in carcinoma cells to reduce invasion and metastasis (33, 34, 42-44), it is 159 
also relevant to evaluate the electrophysiological effects of ESL and S-Lic on this isoform. We 160 
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therefore evaluated the effect of both compounds on Nav1.5 current properties using whole-cell patch 161 
clamp recording, employing a two-pronged approach: (1) recording Nav1.5 currents endogenously 162 
expressed in the MDA-MB-231 breast cancer cell line (29, 30, 45), and (2) recording from Nav1.5 163 
stably over-expressed in HEK-293 cells (HEK-Nav1.5) (46).  164 
Initially, we evaluated the effect of both compounds on the size of the peak Na+ current in MDA-165 
MB-231 cells. Na+ currents were elicited by depolarising the membrane potential (Vm) to -10 mV 166 
from a holding potential (Vh) of -120 mV or -80 mV. Application of the prodrug ESL (300 μM) 167 
reversibly inhibited the transient Na+ current by 49.6 ± 3.2 % when the Vh was -120 mV (P < 0.001; 168 
n = 13; ANOVA + Tukey test; Figure 2A, D). When Vh was set to -80 mV, ESL (300 μM) reversibly 169 
inhibited the transient Na+ current by 79.5 ± 4.5 % (P < 0.001; n = 12; ANOVA + Tukey test; Figure 170 
2C, E). We next assessed the effect of ESL in HEK-Nav1.5 cells. Application of ESL (300 μM) 171 
inhibited Nav1.5 current by 74.7 ± 4.3 % when Vh was -120 mV (P < 0.001; n = 12; Figure 2F, I) and 172 
by 90.5 ± 2.8 % when Vh was -80 mV (P < 0.001; n = 14; Figure 2H, J). However, the inhibition was 173 
only partially reversible (P < 0.001; n = 14; Figure 2F, H-J). Application of ESL at a lower 174 
concentration (100 µM) elicited a similar result (Supplementary Figure 2A-J & Supplementary Table 175 
1). Together, these data suggest that ESL preferentially inhibited Nav1.5 in the open or inactivated 176 
state, since the current inhibition was greater at more depolarised Vh. 177 
We next tested the effect of the active metabolite S-Lic. S-Lic (300 μM) inhibited the transient Na+ 178 
current in MDA-MB-231 cells by 44.4 ± 6.1 % when the Vh was -120 mV (P < 0.001; n = 9; 179 
ANOVA + Tukey test; Figure 3A, D). When Vh was set to -80 mV, S-Lic (300 µM) inhibited the 180 
transient Na+ current by 73.6 ± 4.1 % (P < 0.001; n = 10; ANOVA + Tukey test; Figure 3C, E). 181 
However, the inhibition caused by S-Lic (300 μM) was only partially reversible (P < 0.05; n = 10; 182 
ANOVA + Tukey test; Figure 3A, C-E). In HEK-Nav1.5 cells, S-Lic (300 μM) inhibited Nav1.5 183 
current by 46.4 ± 3.9 % when Vh was -120 mV (P < 0.001; n = 13; ANOVA + Tukey test; Figure 3F, 184 
I) and by 74.0 ± 4.2 % when Vh was -80 mV (P < 0.001; n = 12; ANOVA + Tukey test; Figure 3H, 185 
J). Furthermore, the inhibition in HEK-Nav1.5 cells was not reversible over the duration of the 186 
experiment. Application of S-Lic at a lower concentration (100 µM) elicited a broadly similar result 187 
(Supplementary Figure 3A-J & Supplementary Table 1). Together, these data show that channel 188 
inhibition by S-Lic was also more effective at more depolarised Vh. However, unlike ESL, channel 189 
blockade by S-Lic persisted after washout, suggesting higher target binding affinity for the active 190 
metabolite and/or greater trapping of the active metabolite in the cytoplasm. 191 
We also assessed the effect of both compounds on the persistent Na+ current measured 20-25 ms after 192 
depolarisation to -10 mV from -120 mV. In MDA-MB-231 cells, ESL (300 μM) inhibited the 193 
persistent Na+ current by 77 ± 34 % although the reduction was not statistically significant (P = 0.13; 194 
n = 12; paired t test; Figure 2B, Table 1). In HEK-Nav1.5 cells, ESL (300 μM) inhibited persistent 195 
current by 76 ± 10 % (P < 0.01; n = 12; paired t test; Figure 2G, Table 1). S-Lic (300 μM) inhibited 196 
the persistent Na+ current in MDA-MB-231 cells by 66 ± 16 % (P < 0.05; n = 9; paired t test; Figure 197 
3B, Table 2). In HEK-Nav1.5 cells, S-Lic (300 μM) inhibited persistent current by 35 ± 16 % (P < 198 
0.05; n = 11; Figure 3G, Table 2). Application of both compounds at a lower concentration (100 µM) 199 
elicited a similar result (Supplementary Table 1). In summary, both ESL and S-Lic also inhibited the 200 
persistent Na+ current. 201 
3.2! Effect of eslicarbazepine acetate and S-licarbazepine on voltage dependence of activation 202 
and inactivation 203 
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We next investigated the effect of ESL (300 µM) and S-Lic (300 µM) on the I-V relationship in 204 
MDA-MB-231 and HEK-Nav1.5 cells. A Vh of -120 mV was used for subsequent analyses to ensure 205 
that the elicited currents were sufficiently large for analysis of kinetics and voltage dependence, 206 
particularly for MDA-MB-231 cells, which display smaller peak Na+ currents (Tables 1, 2). Neither 207 
ESL nor S-Lic had any effect on the threshold voltage for activation (Figure 4A-D; Tables 1, 2). ESL 208 
also had no effect on the voltage at current peak in either cell line (Figure 4A-D; Tables 1, 2). 209 
Although S-Lic had no effect on voltage at current peak in MDA-MB-231 cells, it was significantly 210 
hyperpolarised in HEK-Nav1.5 cells from -18.0 ± 4.2 mV to -30.0 ± 5.6 mV (P < 0.001; n = 9; paired 211 
t test; Figure 4A-D; Tables 1, 2). 212 
ESL had no significant effect on the half-activation voltage (V½) or slope factor (k) for activation in 213 
MDA-MB-231 cells (Figure 5A; Table 1). The activation k in HEK-Nav1.5 cells was also unchanged 214 
but the activation V½ was significantly hyperpolarised by ESL from -39.4 ± 1.3 to -44.2 ± 1.8 mV (P 215 
< 0.05; n = 10; paired t test; Figure 5B; Table 1). S-Lic also had no significant effect on the activation 216 
V½ or k in MDA-MB-231 cells (Figure 5C; Table 2). However, the V½ of activation in HEK-Nav1.5 217 
cells was significantly hyperpolarised from -32.8 ± 3.1 mV to -40.5 ± 3.4 mV (P < 0.01; n = 9; paired 218 
t test; Figure 5D; Table 2) and k changed from 5.9 ± 0.9 mV to 4.5 ± 1.1 mV (P < 0.05; n = 9; paired 219 
t test; Figure 5D; Table 2).  220 
As regards steady-state inactivation, in MDA-MB-231 cells, ESL significantly hyperpolarised the 221 
inactivation V½ from -80.6 ± 0.7 mV to -86.7 ± 1.2 mV (P < 0.001; n = 13; paired t test) without 222 
affecting inactivation k (Figure 5A; Table 1). ESL also hyperpolarised the inactivation V½ in HEK-223 
Nav1.5 cells from -78.2 ± 2.5 mV to -88.3 ± 2.7 mV (P < 0.001; n = 10; paired t test), and changed 224 
the inactivation k from -6.9 ± 0.4 mV to -9.8 ± 0.7 mV (P < 0.001; n = 10; paired t test; Figure 5B; 225 
Table 1). S-Lic also significantly hyperpolarised the inactivation V½ in MDA-MB-231 cells from -226 
71.8 ± 2.5 mV to -76.8 ± 2.2 mV (P < 0.05; n = 7; paired t test) without affecting inactivation k 227 
(Figure 5C; Table 2). However, the inactivation V½ in HEK-Nav1.5 cells was not significantly 228 
altered by S-Lic, although the inactivation k significantly changed from -6.5 ± 0.4 mV to -8.1 ± 0.5 229 
mV (P < 0.05; n = 9; paired t test; Figure 5D; Table 2). In summary, both ESL and S-Lic affected 230 
various aspects of the voltage dependence characteristics of Nav1.5 in MDA-MB-231 and HEK-231 
Nav1.5 cells, predominantly hyperpolarising the voltage dependence of inactivation. 232 
3.3! Effect of eslicarbazepine acetate and S-licarbazepine on activation and inactivation 233 
kinetics 234 
We next studied the effect of both compounds on kinetics of activation and inactivation. In MDA-235 
MB-231 cells, ESL (300 μM) significantly accelerated the time to peak current (Tp), upon 236 
depolarisation from -120 mV to -10 mV, from 2.1 ± 0.2 ms to 1.9 ± 0.2 ms (P < 0.01; n = 13; paired t 237 
test; Table 1). However, in HEK-Nav1.5 cells, ESL significantly slowed Tp from 1.4 ± 0.2 ms to 1.5 ± 238 
0.2 ms (P < 0.001; n = 14; paired t test; Table 1). S-Lic (300 μM) had no significant effect on Tp in 239 
MDA-MB-231 cells but significantly slowed Tp in HEK-Nav1.5 cells from 1.8 ± 0.5 ms to 2.3 ± 0.6 240 
ms (P < 0.01; n = 13; paired t test; Table 2). 241 
To study effects on inactivation kinetics, the current decay following depolarisation from -120 mV to 242 
-10 mV was fitted to a double exponential function to derive fast and slow time constants of 243 
inactivation (tf and ts). Neither ESL nor S-Lic had any significant effect on tf or ts in MDA-MB-231 244 
cells (Tables 1, 2). However, in HEK-Nav1.5 cells, ESL significantly slowed tf from 0.9 ± 0.1 ms to 245 
1.2 ± 0.1 ms (P < 0.001; n = 12; paired t test; Table 1) and slowed ts from 6.6 ± 0.8 ms to 20.8 ± 8.5 246 
ms, although this was not statistically significant. S-Lic significantly slowed tf from 1.0 ± 0.04 ms to 247 
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1.3 ± 0.06 ms (P < 0.001; n = 11; paired t test; Table 2) and ts from 6.3 ± 0.5 ms to 7.3 ± 0.5 ms (P < 248 
0.05; n = 11; paired t test; Table 2). In summary, both ESL and S-Lic elicited various effects on 249 
kinetics in MDA-MB-231 and HEK-Nav1.5 cells, predominantly slowing activation and inactivation. 250 
3.4! Effect of eslicarbazepine acetate and S-licarbazepine on recovery from fast inactivation 251 
To investigate the effect of ESL and S-Lic on channel recovery from fast inactivation, we subjected 252 
cells to two depolarisations from Vh of -120 mV to 0 mV, changing the interval between these in 253 
which the channels were held at -120 mV to facilitate recovery. Significance was determined by 254 
fitting a single exponential curve to the normalised current/time relationship and calculating the time 255 
constant (tr). In MDA-MB-231 cells, ESL (300 μM) significantly slowed tr from 6.0 ± 0.5 ms to 8.7 256 
± 0.7 ms (P < 0.05; n = 10; paired t test; Figure 6A, Table 1). Similarly, in HEK-Nav1.5 cells, ESL 257 
significantly slowed tr from 4.5 ± 0.4 ms to 7.1 ± 0.6 ms (P < 0.001; n = 10; paired t test; Figure 6B, 258 
Table 1). S-Lic (300 μM) also significantly slowed tr in MDA-MB-231 cells from 6.8 ± 0.4 ms to 259 
13.5 ± 1.0 ms (P < 0.01; n = 7; paired t test; Figure 6C, Table 2). Finally, S-Lic also significantly 260 
slowed tr in HEK-Nav1.5 cells from 5.7 ± 0.7 ms to 8.0 ± 1.2 ms (P < 0.01; n = 10; paired t test; 261 
Figure 6D, Table 2). In summary, both ESL and S-Lic slowed recovery from fast inactivation of 262 
Nav1.5. 263 
4! Discussion 264 
In this study, we have shown that ESL and its active metabolite S-Lic inhibit the transient and 265 
persistent components of Na+ current carried by Nav1.5. We show broadly similar effects in MDA-266 
MB-231 cells, which express endogenous Nav1.5 (29, 30, 45), and in HEK-293 cells over-expressing 267 
Nav1.5. Notably, both compounds were more effective when Vh was set to -80 mV than at -120 mV, 268 
suggestive of depolarised state-dependent binding. In addition, the inhibitory effect of ESL was 269 
reversible whereas inhibition by S-Lic was less so. As regards voltage-dependence, both ESL and S-270 
Lic shifted activation and steady-state inactivation curves, to varying extents in the two cell lines, in 271 
the direction of more negative voltages. ESL and S-Lic had various effects on activation and 272 
inactivation kinetics, generally slowing the rate of inactivation. Finally, recovery from fast 273 
inactivation of Nav1.5 was significantly slowed by both ESL and S-Lic.  274 
To our knowledge, this is the first time that the effects of ESL and S-Lic have specifically been tested 275 
on the Nav1.5 isoform. A strength of this study is that both the prodrug (ESL) and the active 276 
metabolite (S-Lic) were tested using two independent cell lines, one endogenously expressing 277 
Nav1.5, the other stably over-expressing Nav1.5. MDA-MB-231 cells also express Nav1.7, although 278 
this isoform is estimated to be responsible for only ~9 % of the total VGSC current (30, 45). MDA-279 
MB-231 cells also express endogenous β1, β2 and β4 subunits (47-49). MDA-MB-231 cells 280 
predominantly express the developmentally regulated ‘neonatal’ Nav1.5 splice variant, which differs 281 
from the ‘adult’ variant over-expressed in the HEK-Nav1.5 cells by seven amino acids located in the 282 
extracellular linker between transmembrane segments 3 and 4 of domain 1 (30, 42, 45). Notably, 283 
however, there were no consistent differences in effect of either ESL or S-Lic between the MDA-284 
MB-231 and HEK-Nav1.5 cells, suggesting that the neonatal vs. adult splicing event, and/or 285 
expression of endogenous β subunits, does not impact on sensitivity of Nav1.5 to these compounds. 286 
This finding contrasts another report showing different sensitivity of the neonatal and adult Nav1.5 287 
splice variants to the amide local anaesthetics lidocaine and levobupivacaine (44). Our findings 288 
suggest that the inhibitory effect of S-Lic on Nav1.5 is less reversible than that of ESL. This may be 289 
explained by the differing chemical structures of the two molecules possibly enabling S-Lic to bind 290 
the target with higher affinity than ESL. Most VGSC-targeting anticonvulsants, including phenytoin, 291 
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lamotrigine and carbamazepine, block the pore by binding via aromatic-aromatic interaction to a 292 
tyrosine and phenylalanine located in the S6 helix of domain 4 (50). However, S-Lic has been 293 
proposed to bind to a different site given that it was found to block the pore predominantly during 294 
slow inactivation (10). Alternatively, the hydroxyl group present on S-Lic (but not ESL) may become 295 
deprotonated, potentially trapping it in the cytoplasm. 296 
The findings presented here broadly agree with in vitro concentrations used elsewhere to study 297 
effects of ESL and S-Lic on Na+ currents. For example, using a Vh of -80 mV, 300 µM ESL was 298 
shown to inhibit peak Na+ current by 50 % in N1E-115 neuroblastoma cells expressing Nav1.1, 299 
Nav1.2, Nav1.3, Nav1.6 and Nav1.7 (20). S-Lic (250 µM) also blocks peak Na+ current by ~50 % in 300 
the same cell line (10). In addition, S-Lic (300 µM) reduces persistent Na+ current by ~25 % in 301 
acutely isolated murine hippocampal CA1 neurons expressing Nav1.1, Nav1.2 and Nav1.6 (21-24). 302 
Similar to the present study, ESL was shown to hyperpolarise the voltage-dependence of steady-state 303 
inactivation in N1E-115 cells (20). On the other hand, similar to our finding in HEK-Nav1.5 cells, S-304 
Lic has no effect on steady-state inactivation in N1E-115 cells (10). Again, in agreement with our 305 
own findings for Nav1.5, S-Lic slows recovery from inactivation in N1E-115 cells (10). These 306 
observations suggest that the sensitivity of Nav1.5 to ESL and S-Lic is broadly similar to that 307 
reported for neuronal VGSCs. In support of this, Nav1.5 shares the same conserved residues proposed 308 
for Nav1.2 to interact with ESL (Figure 7) (51). 309 
Notably, the concentrations used in this study are at or above those achieved in clinical use (e.g. ESL 310 
1200 mg once daily gives a peak plasma concentration of ~100 µM) (10). However, it has been 311 
argued that the relatively high concentrations which have been previously tested in vitro are clinically 312 
relevant given that S-Lic has a high (50:1) lipid:water partition co-efficient and thus would be 313 
expected to reside predominantly in the tissue membrane fraction in vivo (15). Our study suggests 314 
that a clinically relevant plasma concentration (100 µM) would inhibit peak and persistent Nav1.5 315 
currents. Future work investigating the dose-dependent effects of ESL and S-Lic would be useful to 316 
aid clinical judgements.  317 
The data presented here raise several implications for clinicians. The observed inhibition of Nav1.5 is 318 
worthy of note when considering cardiac function in patients receiving ESL (13). Although the QT 319 
interval remains unchanged for individuals on ESL treatment, prolongation of the PR interval has 320 
been observed (27). Further work is required to establish whether the basis for this PR prolongation 321 
is indeed via Nav1.5 inhibition. In addition, it would be of interest to investigate the efficacy of ESL 322 
and S-Lic in the context of heritable arrhythmogenic mutations in SCN5A, as well as the possible 323 
involvement of the b subunits (24, 26, 52, 53). The findings presented here are also relevant in the 324 
context of Nav1.5 expression in carcinoma cells (54). Given that cancer cells have a relatively 325 
depolarised Vm, it is likely that Nav1.5 is mainly in the inactivated state with the persistent Na+ 326 
current being functionally predominant (55, 56). Increasing evidence suggests that persistent Na+ 327 
current carried by Nav1.5 in cancer cells contributes to invasion and several studies have shown that 328 
other VGSC inhibitors reduce metastasis in preclinical models (29-35, 57). Thus, use-dependent 329 
inhibition by ESL would ensure that channels in malignant cells are particularly targeted, raising the 330 
possibility that it could be used as an anti-metastatic agent (43). This study therefore paves the way 331 
for future investigations into ESL and S-Lic as potential invasion inhibitors. 332 
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10.1! Figure legends 507 
Figure 1. Chemical structures of eslicarbazepine acetate and S-licarbazepine. (A) eslicarbazepine 508 
acetate; (9S)-2-carbamoyl-2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-9-yl acetate. 509 
(B) S-licarbazepine; (10R)-10-hydroxy-2-azatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaene-510 
2-carboxamide. Structures were drawn using Chemspider software. 511 
Figure 2. Effect of eslicarbazepine acetate on Nav1.5 currents. (A) Representative Na+ currents in an 512 
MDA-MB-231 cell elicited by a depolarisation from -120 mV to -10 mV in physiological saline 513 
solution (PSS; black), eslicarbazepine acetate (ESL; 300 μM; red) and after washout (grey). Dotted 514 
vertical lines define the time period magnified in (B). (B) Representative persistent Na+ currents in an 515 
MDA-MB-231 cell elicited by a depolarisation from -120 mV to -10 mV. (C) Representative Na+ 516 
currents in an MDA-MB-231 cell elicited by a depolarisation from -80 mV to -10 mV. (D) 517 
Normalised Na+ currents in MDA-MB-231 cells elicited by a depolarisation from -120 mV to -10 518 
mV. (E) Normalised Na+ currents in MDA-MB-231 cells elicited by a depolarisation from -80 mV to 519 
-10 mV. (F) Representative Na+ currents in a HEK-Nav1.5 cell elicited by a depolarisation from -120 520 
mV to -10 mV in PSS (black), ESL (300 μM; red) and after washout (grey). Dotted vertical lines 521 
define the time period magnified in (G). (G) Representative persistent Na+ currents in a HEK-Nav1.5 522 
cell elicited by a depolarisation from -120 mV to -10 mV. (H) Representative Na+ currents in a HEK-523 
Nav1.5 cell elicited by a depolarisation from -80 mV to -10 mV. (I) Normalised Na+ currents in HEK-524 
Nav1.5 cells elicited by a depolarisation from -120 mV to -10 mV. (J) Normalised Na+ currents in 525 
HEK-Nav1.5 cells elicited by a depolarisation from -80 mV to -10 mV. Results are mean + SEM. *P 526 
≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; one-way ANOVA with Tukey tests (n = 12-14). NS, not 527 
significant. 528 
Figure 3. Effect of S-licarbazepine on Nav1.5 currents. (A) Representative Na+ currents in an MDA-529 
MB-231 cell elicited by a depolarisation from -120 mV to -10 mV in physiological saline solution 530 
(PSS; black), S-licarbazepine (S-Lic; 300 μM; red) and after washout (grey). Dotted vertical lines 531 
define the time period magnified in (B). (B) Representative persistent Na+ currents in an MDA-MB-532 
231 cell elicited by a depolarisation from -120 mV to -10 mV. (C) Representative Na+ currents in an 533 
MDA-MB-231 cell elicited by a depolarisation from -80 mV to -10 mV. (D) Normalised Na+ 534 
currents in MDA-MB-231 cells elicited by a depolarisation from -120 mV to -10 mV. (E) 535 
Normalised Na+ currents in MDA-MB-231 cells elicited by a depolarisation from -80 mV to -10 mV. 536 
(F) Representative Na+ currents in a HEK-Nav1.5 cell elicited by a depolarisation from -120 mV to -537 
10 mV in PSS (black), S-Lic (300 μM; red) and after washout (grey). Dotted vertical lines define the 538 
time period magnified in (G). (G) Representative persistent Na+ currents in a HEK-Nav1.5 cell 539 
elicited by a depolarisation from -120 mV to -10 mV. (H) Representative Na+ currents in a HEK-540 
Nav1.5 cell elicited by a depolarisation from -80 mV to -10 mV. (I) Normalised Na+ currents in HEK-541 
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Nav1.5 cells elicited by a depolarisation from -120 mV to -10 mV. (J) Normalised Na+ currents in 542 
HEK-Nav1.5 cells elicited by a depolarisation from -80 mV to -10 mV. Results are mean + SEM. *P 543 
≤ 0.05; ***P ≤ 0.001; one-way ANOVA with Tukey tests (n = 9-13). NS, not significant. 544 
Figure 4. Effect of eslicarbazepine acetate and S-licarbazepine on the current-voltage relationship. 545 
(A) Current-voltage (I-V) plots of Na+ currents in MDA-MB-231 cells in physiological saline 546 
solution (PSS; black circles) and in eslicarbazepine acetate (ESL; 300 μM; red squares). (B) (I-V) 547 
plots of Na+ currents in HEK-Nav1.5 cells in PSS (black circles) and ESL (300 μM; red squares). (C) 548 
I-V plots of Na+ currents in MDA-MB-231 cells in PSS (black circles) and S-licarbazepine (S-Lic; 549 
300 μM; red squares). (D) I-V plots of Na+ currents in HEK-Nav1.5 cells in PSS (black circles) and 550 
S-Lic (300 μM; red squares). Currents were elicited using 10 mV depolarising steps from -80 to +30 551 
mV for 30 ms, from a holding potential of -120 mV. Results are mean ± SEM (n = 7-13). 552 
Figure 5. Effect of eslicarbazepine acetate and S-licarbazepine on activation and steady-state 553 
inactivation. (A) Activation and steady-state inactivation in MDA-MB-231 cells in physiological 554 
saline solution (PSS; black circles) and in eslicarbazepine acetate (ESL; 300 μM; red squares). (B) 555 
Activation and steady-state inactivation in HEK-Nav1.5 cells in PSS (black circles) and ESL (300 556 
μM; red squares). (C) Activation and steady-state inactivation in MDA-MB-231 cells in PSS (black 557 
circles) and S-licarbazepine (S-Lic; 300 μM; red squares). (D) Activation and steady-state 558 
inactivation in HEK-Nav1.5 cells in PSS (black circles) and S-Lic (300 μM; red squares). For 559 
activation, normalised conductance (G/Gmax) was calculated from the current data and plotted as a 560 
function of voltage. For steady-state inactivation, normalised current (I/Imax), elicited by 50 ms test 561 
pulses at -10 mV following 250 ms conditioning voltage pulses between -120 mV and +30 mV, 562 
applied from a holding potential of -120 mV, was plotted as a function of the prepulse voltage. 563 
Results are mean ± SEM (n = 7-13). Activation and inactivation curves are fitted with Boltzmann 564 
functions. 565 
Figure 6. Effect of eslicarbazepine acetate and S-licarbazepine on recovery from inactivation. (A) 566 
Recovery from inactivation in MDA-MB-231 cells in physiological saline solution (PSS; black 567 
circles) and in eslicarbazepine acetate (ESL; 300 μM; red squares). (B) Recovery from inactivation in 568 
HEK-Nav1.5 cells in PSS (black circles) and ESL (300 μM; red squares). (C) Recovery from 569 
inactivation in MDA-MB-231 cells in PSS (black circles) and S-licarbazepine (S-Lic; 300 μM; red 570 
squares). (D) Recovery from inactivation in HEK-Nav1.5 cells in PSS (black circles) and S-Lic (300 571 
μM; red squares). The fraction recovered (It/Ic) was determined by a 25 ms pulse to 0 mV (Ic), 572 
followed by a recovery pulse to -120 mV for 1-500 ms, and a subsequent 25 ms test pulse to 0 mV 573 
(It), applied from a holding potential of -120 mV, and plotted as a function of the recovery interval. 574 
Data are fitted with single exponential functions which are statistically different between control and 575 
drug treatments in all cases. Results are mean ± SEM (n = 7-10). 576 
Figure 7. Clustal alignment of amino acid sequences of Nav1.1-Nav1.9 (SCN1A-SCN11A). ESL was 577 
proposed previously (51) to interact with the highlighted amino acids in Nav1.2. An alignment of 578 
Nav1.2 (UniProtKB - Q99250 (SCN2A_HUMAN)) with Nav1.1 (UniProtKB - P35498 579 
(SCN1A_HUMAN)), Nav1.3 (UniProtKB - Q9NY46 (SCN3A_HUMAN)), Nav1.4 (UniProtKB - 580 
P35499 (SCN4A_HUMAN)), Nav1.5 (UniProtKB - Q14524 (SCN5A_HUMAN)) Nav1.6 581 
(UniProtKB - Q9UQD0 (SCN8A_HUMAN)), Nav1.7 (UniProtKB - Q15858 (SCN9A_HUMAN)), 582 
Nav1.8 (UniProtKB - Q9Y5Y9 (SCN10A_HUMAN)), and Nav1.9 (UniProtKB - Q9UI33 583 
(SCN11A_HUMAN)) shows that the interacting amino acids highlighted in yellow are conserved 584 
between Nav1.2 and Nav1.5, along with most other isoforms. Asterisks indicate conserved residues. 585 
Colon indicates conservation between groups of strongly similar properties - scoring > 0.5 in the 586 
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Gonnet PAM 250 matrix. Period indicates conservation between groups of weakly similar properties 587 
- scoring ≤ 0.5 in the Gonnet PAM 250 matrix. 588 
  589 
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Table 1. Effect of eslicarbazepine acetate (300 μM) on Na+ current characteristics in MDA-MB-231 590 
and HEK-Nav1.5 cells.1 591 
A. MDA-MB-231 cells 
   
 
Parameter Control ESL P value N 
Vthres (mV) -45.7 ± 1.7 -45.0 ± 1.4 0.58 13 
Vpeak (mV) 3.1 ± 2.1 -3.9 ± 2.7 0.056 13 
Activation V½ (mV) -19.3 ± 1.4 -22.0 ± 1.5 0.095 12 
Activation k (mV) 10.6 ± 0.7 9.3 ± 0.8 0.076 12 
Inactivation V½ (mV) -80.6 ± 0.7 -86.7 ± 1.2 <0.001 13 
Inactivation k (mV) -4.8 ± 0.4 -7.4 ± 1.7 0.139 13 
Peak current density at -10 mV (pA/pF) -14.8 ± 3.9 -8.0 ± 2.5 <0.001 13 
Persistent current density at -10 mV (pA/pF) -0.15 ± 0.05 -0.02 ± 0.07 0.13 12 
Tp at -10 mV (ms) 2.1 ± 0.2 1.9 ± 0.2 <0.01 13 
tf at -10 mV (ms) 1.3 ± 0.1 1.3 ± 0.2 0.954 13 
ts at -10 mV) (ms) 10.0 ± 2.3 6.9 ± 2.0 0.289 13 
tr (ms) 6.0 ± 0.5 8.7 ± 0.7 <0.05 10 
B. HEK-Na!1.5 cells 
   
 
Parameter Control ESL P value N 
Vthres (mV) -55.0 ± 1.7 -54.0 ± 2.2 0.758 10 
Vpeak (mV) -26.0 ± 2.2 -24.0 ± 4.3 0.591 10 
Activation V½ (mV) -39.4 ± 1.3 -44.2 ± 1.8 <0.05 10 
Activation k (mV) 5.3 ± 1.3 3.8 ± 0.7 0.361 10 
Inactivation V½ (mV) -78.2 ± 2.5 -88.3 ± 2.7 <0.001 10 
Inactivation k (mV) -6.9 ± 0.4 -9.8 ± 0.7 <0.001 10 
Peak current density at -10 mV (pA/pF) -154.4 ± 24.0 -33.1 ± 4.7 <0.001 12 
Persistent current density at -10 mV (pA/pF) -0.61 ± 0.15 -0.12 ± 0.05 <0.01 12 
Tp at -10 mV (ms) 1.4 ± 0.2 1.9 ± 0.2 <0.001 14 
tf at -10 mV (ms) 0.9 ± 0.1 1.2 ± 0.1 <0.001 12 
ts at -10 mV (ms) 6.6 ± 0.8 20.8 ± 8.5 0.128 12 
tr (ms) 4.5 ± 0.4 7.1 ± 0.6 <0.001 10 
1ESL: eslicarbazepine acetate (300 µM); Vthres: threshold voltage for activation; Vpeak: voltage at 592 
which current was maximal; V!: half (in)activation voltage; k: slope factor for (in)activation; Tp: 593 
time to peak current;  tf: fast time constant of inactivation;  ts: slow time constant of inactivation; tr: 594 
time constant of recovery from inactivation. The holding potential was -120 mV. Results are mean ± 595 
SEM. Statistical comparisons were made with paired t-tests.  596 
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Table 2. Effect of S-licarbazepine (300 μM) on Na+ current characteristics in MDA-MB-231 and 597 
HEK-Nav1.5 cells.1 598 
A. MDA-MB-231 cells     
Parameter Control S-Lic P value N 
Vthres (mV) -34.4 ± 2.0 -35.7 ± 2.0 0.603 7 
Vpeak (mV) 11.43 ± 4.4 10.0 ± 4.9 0.818 7 
Activation V½ (mV) -12.9 ± 1.3 -13.7 ± 1.4 0.371 7 
Activation k (mV) 11.0 ± 0.5 11.9 ± 0.8 0.520 7 
Inactivation V½ (mV) -71.8 ± 2.5 -76.8 ± 2.2 <0.05 7 
Inactivation k (mV) -6.8 ± 0.9 -6.0 ± 1.2 0.302 7 
Peak current density at -10 mV (pA/pF) -12.0 ± 3.1 -6.9 ± 2.5 <0.001 9 
Persistent current density at -10 mV (pA/pF) -1.3 ± 0.4 -0.6 ± 0.2 <0.05 9 
Tp at -10 mV (ms) 4.5 ± 0.4 5.1 ± 0.7 0.103 9 
tf at -10 mV (ms) 3.8 ± 1.1 3.2 ± 0.4 0.553 7 
ts at -10 mV (ms) 25.7 ± 7.0 27.1 ± 12.0 0.920 7 
tr (ms) 6.8 ± 0.4 13.5 ± 1.0 <0.01 7 
B. HEK-Na!1.5 cells     
Parameter Control S-Lic P value N 
Vthres (mV) -50.0 ± 1.9 -51.3 ± 3.5 0.598 9 
Vpeak (mV) -18.0 ± 4.2 -30.0 ± 5.6 <0.001 9 
Activation V½ (mV) -32.8 ± 3.1 -40.5 ± 3.4 <0.01 9 
Activation k (mV) 5.9 ± 0.9 4.5 ± 1.1 <0.05 9 
Inactivation V½ (mV) -75.9 ± 2.6 -79.3 ± 4.1 0.116 9 
Inactivation k (mV) -6.5 ± 0.4 -8.1 ± 0.5 <0.05 9 
Peak current density at -10 mV (pA/pF) -140.9 ± 26.8 -77.2 ± 17.0 <0.001 13 
Persistent current density at -10 mV (pA/pF) -0.9 ± 0.2 -0.5 ± 0.2 <0.05 11 
Tp at -10 mV (ms) 1.8 ± 0.5 2.3 ± 0.6 <0.01 13 
tf at -10 mV (ms) 1.0 ± 0.04 1.3 ± 0.06 <0.001 11 
ts at -10 mV (ms) 6.3 ± 0.5 7.3 ± 0.5 <0.05 11 
tr (ms) 5.7 ± 0.7 8.0 ± 1.2 <0.01 10 
1S-Lic: S-licarbazepine (300 µM); Vthres: threshold voltage for activation; Vpeak: voltage at which 599 
current was maximal; V!: half (in)activation voltage; k: slope factor for (in)activation; Tp: time to 600 
peak current;  tf: fast time constant of inactivation;  ts: slow time constant of inactivation; tr: time 601 
constant of recovery from inactivation. The holding potential was -120 mV. Results are mean ± SEM. 602 
Statistical comparisons were made with paired t-tests. 603 
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Figure 1 604 
 605 
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Figure 3 609 
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Figure 4 611 
 612 
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Figure 5 614 
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Figure 6 617 
 618 
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Figure 7 620 
 621 
  622 
SCN1A ILENFSVATEESAEPLSEDDFEMFYEVWEKFDPDATQFMEFEKLSQFAAALEPPLNLPQP 1844
SCN2A ILENFSVATEESAEPLSEDDFEMFYEVWEKFDPDATQFIEFAKLSDFADALDPPLLIAKP 1834
SCN3A ILENFSVATEESAEPLSEDDFEMFYEVWEKFDPDATQFIEFSKLSDFAAALDPPLLIAKP 1829
SCN4A ILENFNVATEESSEPLGEDDFEMFYETWEKFDPDATQFIAYSRLSDFVDTLQEPLRIAKP 1656
SCN5A ILENFSVATEESTEPLSEDDFDMFYEIWEKFDPEATQFIEYSVLSDFADALSEPLRIAKP 1830
SCN8A ILENFSVATEESADPLSEDDFETFYEIWEKFDPDATQFIEYCKLADFADALEHPLRVPKP 1824
SCN9A ILENFSVATEESTEPLSEDDFEMFYEVWEKFDPDATQFIEFSKLSDFAAALDPPLLIAKP 1818
SCN10A ILENFNVATEESTEPLSEDDFDMFYETWEKFDPEATQFITFSALSDFADTLSGPLRIPKP 1780
SCN11A ILENFNTATEESEDPLGEDDFDIFYEVWEKFDPEATQFIKYSALSDFADALPEPLRVAKP 1662
*****..***** :**.****: *** ******:****: : *::*. :* ** : :*
SCN1A NKLQLIAMDLPMVSGDRIHCLDILFAFTKRVLGESGEMDALRIQMEERFMASNPSKVSYQ 1904
SCN2A NKVQLIAMDLPMVSGDRIHCLDILFAFTKRVLGESGEMDALRIQMEERFMASNPSKVSYE 1894
SCN3A NKVQLIAMDLPMVSGDRIHCLDILFAFTKRVLGESGEMDALRIQMEDRFMASNPSKVSYE 1889
SCN4A NKIKLITLDLPMVPGDKIHCLDILFALTKEVLGDSGEMDALKQTMEEKFMAANPSKVSYE 1716
SCN5A NQISLINMDLPMVSGDRIHCMDILFAFTKRVLGESGEMDALKIQMEEKFMAANPSKISYE 1890
SCN8A NTIELIAMDLPMVSGDRIHCLDILFAFTKRVLGDSGELDILRQQMEERFVASNPSKVSYE 1884
SCN9A NKVQLIAMDLPMVSGDRIHCLDILFAFTKRVLGESGEMDSLRSQMEERFMSANPSKVSYE 1878
SCN10A NRNILIQMDLPLVPGDKIHCLDILFAFTKNVLGESGELDSLKANMEEKFMATNLSKSSYE 1840
SCN11A NKYQFLVMDLPMVSEDRLHCMDILFAFTARVLGGSDGLDSMKAMMEEKFMEANPLKKLYE 1722
* :: :***:* *::**:*****:* .*** *. :* :: **::*: :* * *:
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Supplementary Table 1A. Effect of eslicarbazepine acetate (100 μM) on peak and persistent Na+ 623 
current in MDA-MB-231 and HEK-Nav1.5 cells. 624 
 625 
A. MDA-MB-231 cells 
   
 
Parameter Control ESL P value N 
Peak current density at -10 mV, 
Vh -120 mV (pA/pF) 
-22.1 ± 13.5 -11.6 ± 7.9 <0.05 7 
Peak current density at -10 mV, 
Vh -80 mV (pA/pF) 
-7.1 ± 4.1 -2.1 ± 2.0 < 0.05 7 
Persistent current density at -10 mV, 
Vh -120 mV (pA/pF) 
-0.5 ± 0.3 -0.4 ± 0.2 0.277 7 
B. HEK-Nav1.5 cells     
Parameter Control ESL P value N 
Peak current density at -10 mV, 
Vh -120 mV (pA/pF) 
-158.4 ± 85.7 -77.7 ± 51.3 <0.01 8 
Peak current density at -10 mV, 
Vh -80 mV (pA/pF) 
-59.0 ± 50.7 -12.2 ± 11.9 <0.05 8 
Persistent current density at -10 mV, 
Vh -120 mV (pA/pF) 
-1.0 ± 0.3 -0.4 ± 0.1 <0.001 8 
1ESL: eslicarbazepine acetate (100 µM). Results are mean ± SEM. Statistical comparisons were made 626 
with paired t-tests. 627 
 628 
Supplementary Table 1B. Effect of S-licarbazepine (100 μM) on peak and persistent Na+ current in 629 
MDA-MB-231 and HEK-Nav1.5 cells. 630 
 631 
A. MDA-MB-231 cells 
   
 
Parameter Control S-Lic P value N 
Peak current density at -10 mV, 
Vh -120 mV (pA/pF) 
-17.2 ± 8.7 -12.3 ± 7.4 0.084 8 
Peak current density at -10 mV, 
Vh -80 mV (pA/pF) 
-7.8 ± 4.7 -3.5 ± 2.6 <0.05 8 
Persistent current density at -10 mV, 
Vh -120 mV (pA/pF) 
-0.6 ± 0.3 -0.4 ± 0.2 <0.01 8 
B. HEK-Nav1.5 cells     
Parameter Control S-Lic P value N 
Peak current density at -10 mV, 
Vh -120 mV (pA/pF) 
-108.5 ± 20.3 - 75.6 ± 30.9  <0.05 8 
Peak current density at -10 mV, 
Vh -80 mV (pA/pF) 
 -30.2 ± 0.9 -11.8 ± 1.3 <0.001 8 
Persistent current density at -10 mV, 
Vh -120 mV (pA/pF) 
-0.5 ± 0.1 -0.3 ± 0.1 <0.05 7 
1S-Lic: S-licarbazepine (100 µM). Results are mean ± SEM. Statistical comparisons were made with 632 
paired t-tests. 633 
  634 
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Supplementary Figure Legends 635 
Supplementary Figure 1. Effect of 0.45% DMSO on VGSC current-voltage relationship and gating 636 
in MDA-MB-231 cells. (A) Current-voltage (I-V) plots of Na+ currents in MDA-MB-231 cells in 637 
physiological saline solution (PSS; black circles) and in PSS with 0.45% DMSO (0.45% DMSO; 638 
green squares). Currents were elicited using 10 mV depolarising steps from -80 to +30 mV for 30 ms, 639 
from a holding potential of -120 mV. Results are mean ± SEM (n = 13-17). (B) Activation and 640 
steady-state inactivation in physiological saline solution (PSS; black circles) and in PSS with 0.45% 641 
DMSO (0.45% DMSO; green squares). For activation, normalised conductance (G/Gmax) was 642 
calculated from the current data and plotted as a function of voltage. For steady-state inactivation, 643 
normalised current (I/Imax), elicited by 50 ms test pulses at -10 mV following 250 ms conditioning 644 
voltage pulses between -120 mV and +30 mV, applied from a holding potential of -120 mV, was 645 
plotted as a function of the prepulse voltage. Results are mean ± SEM (n = 10-13). Activation and 646 
inactivation curves are fitted with Boltzmann functions. 647 
Supplementary Figure 2. Effect of 100 μM eslicarbazepine acetate on Nav1.5 currents. (A) 648 
Representative Na+ currents in an MDA-MB-231 cell elicited by a depolarisation from -120 mV to -649 
10 mV in physiological saline solution (PSS; black), eslicarbazepine acetate (ESL; 100 μM; red) and 650 
after washout (grey). Dotted vertical lines define the time period magnified in (B). (B) Representative 651 
persistent Na+ currents in an MDA-MB-231 cell elicited by a depolarisation from -120 mV to -10 652 
mV. (C) Representative Na+ currents in an MDA-MB-231 cell elicited by a depolarisation from -80 653 
mV to -10 mV. (D) Normalised Na+ currents in MDA-MB-231 cells elicited by a depolarisation from 654 
-120 mV to -10 mV. (E) Normalised Na+ currents in MDA-MB-231 cells elicited by a depolarisation 655 
from -80 mV to -10 mV. (F) Representative Na+ currents in a HEK-Nav1.5 cell elicited by a 656 
depolarisation from -120 mV to -10 mV in PSS (black), ESL (100 μM; red) and after washout (grey). 657 
Dotted vertical lines define the time period magnified in (G). (G) Representative persistent Na+ 658 
currents in a HEK-Nav1.5 cell elicited by a depolarisation from -120 mV to -10 mV. (H) 659 
Representative Na+ currents in a HEK-Nav1.5 cell elicited by a depolarisation from -80 mV to -10 660 
mV. (I) Normalised Na+ currents in HEK-Nav1.5 cells elicited by a depolarisation from -120 mV to -661 
10 mV. (J) Normalised Na+ currents in HEK-Nav1.5 cells elicited by a depolarisation from -80 mV to 662 
-10 mV. Results are mean + SEM. *P ≤ 0.05; **P ≤ 0.01; one-way ANOVA with Tukey tests (n = 7-663 
8). NS, not significant. 664 
Supplementary Figure 3. Effect of 100 μM S-licarbazepine on Nav1.5 currents. (A) Representative 665 
Na+ currents in an MDA-MB-231 cell elicited by a depolarisation from -120 mV to -10 mV in 666 
physiological saline solution (PSS; black), S-licarbazepine (S-Lic; 100 μM; red) and after washout 667 
(grey). Dotted vertical lines define the time period magnified in (B). (B) Representative persistent 668 
Na+ currents in an MDA-MB-231 cell elicited by a depolarisation from -120 mV to -10 mV. (C) 669 
Representative Na+ currents in an MDA-MB-231 cell elicited by a depolarisation from -80 mV to -10 670 
mV. (D) Normalised Na+ currents in MDA-MB-231 cells elicited by a depolarisation from -120 mV 671 
to -10 mV. (E) Normalised Na+ currents in MDA-MB-231 cells elicited by a depolarisation from -80 672 
mV to -10 mV. (F) Representative Na+ currents in a HEK-Nav1.5 cell elicited by a depolarisation 673 
from -120 mV to -10 mV in PSS (black), S-Lic (100 μM; red) and after washout (grey). Dotted 674 
vertical lines define the time period magnified in (G). (G) Representative persistent Na+ currents in a 675 
HEK-Nav1.5 cell elicited by a depolarisation from -120 mV to -10 mV. (H) Representative Na+ 676 
currents in a HEK-Nav1.5 cell elicited by a depolarisation from -80 mV to -10 mV. (I) Normalised 677 
Na+ currents in HEK-Nav1.5 cells elicited by a depolarisation from -120 mV to -10 mV. (J) 678 
Normalised Na+ currents in HEK-Nav1.5 cells elicited by a depolarisation from -80 mV to -10 mV. 679 
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Results are mean + SEM. *P ≤ 0.05; ***P ≤ 0.001; one-way ANOVA with Tukey tests (n = 7-8). NS, 680 
not significant. 681 
  682 
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Supplementary Figure 1 683 
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Supplementary Figure 2 686 
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Supplementary Figure 3 688 
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